At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating Disulfiram, Copper, and 1 other intervention for Glioma and Glioblastoma. Completed, enrolled 88 participants across 8 sites in 2 countries.
Detailed Summary
Disulfiram (Antabuse®) is a well-tolerated, cheap, generic drug that has been in use since the 1950s to treat alcoholism. There is now an increasing amount of independent preclinical data to support disulfiram as an anticancer agent. The potency of disulfiram as an anticancer agent seems strengthened by copper. The investigators aim is to investigate disulfiram and copper-supplement as add-on treatment in glioblastoma patients with recurrence receiving alkylating chemotherapy.
Study Details
Timeline
Interventions
Disulfiram 400 mg daily
nutritional supplement with copper, 2 mg daily
Alkylating antineoplastic agent